Welcome

Sign out Have a question? We're here to help

Copyright © 2020 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Zscaler Ord Shs (ZS)

$121.00 7.16 (6.29%)

19:15 EDT ZS Stock Quote Delayed 30 Minutes

Volume:

Previous Close $120.85

Market Cap 14.47B

PE Ratio -369.88

EPS -0.327135

Volume (Avg. Vol.) 3.06M

Day's Range 115.41 - 121.01

52-Week Range 35.00 - 121.46

Dividend & Yield N/A (N/A)

ZS Stock Predictions, Articles, and Zscaler Ord Shs News

From the Web

Best & Worst Performing Mega Cap Stocks for July 8, 2020

From StockNews.com Jul 8, 2020

BABA – BABA leads the way today as the best performing mega cap stock, closing up 8.95%.

Glaxo Signs Another Deal to Develop a Coronavirus Vaccine

From Zacks Investment Research Jul 8, 2020

Glaxo (GSK) collaborates with Medicago to develop a vaccine candidate for COVID-19 using Medicago's antigen and Glaxo's adjuvant system.

Sanofi's Sarclisa OK'd in Canada (NASDAQ:SNY)

From Seeking Alpha Jul 8, 2020

Health Canada has approved Sanofi's (NASDAQ:SNY) Sarclisa (isatuximab-irfc) for the treatment of adults with relapsed/refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.The CD38-directed cytolytic antibody was previously approved in the U.S.

Kiadis inks license deal with Sanofi valued as high as €875M (OTCMKTS:KIADF)

From Seeking Alpha Jul 8, 2020

Kiadis Pharma N.V. (OTC:KIADF) has granted an exclusive global license to its K-NK004 cell program to Sanofi (NASDAQ:SNY), including exclusive rights to its K-NK platform for two other preclinical programs (excluding K-NK002 and K-NK003).Under the terms of the deal, Kiadis will receive a €17.5M up front, up to €857.5M in milestones and low double-digit royalties on net sales.The agreement covers Kiadis' proprietary CD38 knockout K-NK therapeutic for use in combination with Sanofi's Sarclisa (isatuximab-irfc), a CD38-directed cytolytic antibody approved in the U.S.

Regeneron Initiates Studies on Experimental Coronavirus Drug

From Zacks Investment Research Jul 7, 2020

Regeneron (REGN) announces initiation of late-stage studies evaluating REGN-COV2 for the treatment and prevention of COVID-19.

Best & Worst Performing Mega Cap Stocks for July 7, 2020

From StockNews.com Jul 7, 2020

WMT – WMT leads the way today as the best performing mega cap stock, closing up 6.78%.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy